Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease.,advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; pregelatinised maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. to suppress 'flare' with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; magnesium stearate; povidone; colloidal anhydrous silica; sodium lauryl sulfate; sodium starch glycollate - temporary relief of acute moderate pain and fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; sodium lauryl sulfate; povidone; purified talc; magnesium stearate; colloidal anhydrous silica; hyprolose; stearic acid - temporary relief of acute moderate pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increases production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if meditab cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation. . men: reduction of drive in sexual deviations. meditab cyproterone reduces the force of the sexual urge in men with sexual deviations. whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. meditab cyproterone therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. inoperable prostatic carcinoma. to suppress "flare" with initial lhrh analogue therapy. in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy..

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 109.267 mg (equivalent: erlotinib, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 163.9 mg (equivalent: erlotinib, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - erlotinib hydrochloride, quantity: 27.317 mg (equivalent: erlotinib, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer erlotinib cipla is indicated for the first-line treatment of patients with advanced (stage iiib) or metasttic (stega iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib cipla is indicated for matintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. erlotinib cipla is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib cipla in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cinacalcet hydrochloride, quantity: 99.191 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (hpt) in patients with end stage renal disease, receiving dialysis (see section 5.1 pharmacodynamic properties, clinical trials). cipla cinacalcet should be used as adjunctive therapy.,cipla cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cipla cinacalcet may be used to treat the biochemical manifestations of primary hpt in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cinacalcet hydrochloride, quantity: 66.128 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (hpt) in patients with end stage renal disease, receiving dialysis (see section 5.1 pharmacodynamic properties, clinical trials). cipla cinacalcet should be used as adjunctive therapy.,cipla cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cipla cinacalcet may be used to treat the biochemical manifestations of primary hpt in patients for whom parathyroidectomy is not a treatment option.